Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILD

Mosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassing the study’s primary endpoint.

Analysts at Leerink Partners described the outcome as a "blowout," noting it far exceeded the modest 20% reduction they had anticipated and highlighted the drug’s potential in a disease area with few approved therapies.

The positive data comes as Roivant recently celebrated its first FDA approval for the skin disease drug Lisraya, and the company has already begun enrolling patients in a Phase 3 study of mosliciguat.